- InvestInvestment SuiteExclusiveFeatures
- PlatformProduct SuiteFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnResourceInvesting GuideEvents
- Partner
- Support
Invest
Platform
Research
Market
Learn
Compare UTI Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.23 | 1.91 |
NAV | ₹272.34 | ₹37.48 |
Fund Started | 01 Aug 2005 | 25 Jun 2018 |
Fund Size | ₹1235.91 Cr | ₹5320.29 Cr |
Exit Load | Exit load of 1% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
3.0
5.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.23
1.91
NAV
₹272.34
₹37.48
Fund Started
01 Aug 2005
25 Jun 2018
Fund Size
₹1235.91 Cr
₹5320.29 Cr
Exit Load
Exit load of 1% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 27.11% | 31.28% |
3 Year | 20.42% | 24.08% |
5 Year | 25.15% | 28.24% |
1 Year
27.11%
31.28%
3 Year
20.42%
24.08%
5 Year
25.15%
28.24%
Holding Analysis
Equity | 97.59% | 98.07% |
Cash | 2.30% | 1.93% |
Equity
97.59%
98.07%
Cash
2.30%
1.93%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.07% |
Cipla Ltd. | 5.75% |
Dr. Reddy's Laboratories Ltd. | 5.28% |
Ajanta Pharma Ltd. | 4.58% |
Glenmark Pharmaceuticals Ltd. | 4.03% |
Gland Pharma Ltd. | 3.83% |
Apollo Hospitals Enterprise Ltd. | 3.54% |
Fortis Healthcare Ltd. | 3.25% |
Procter & Gamble Health Ltd. | 3.14% |
Divi's Laboratories Ltd. | 3.03% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.83% |
Cipla Ltd. | 9.28% |
Dr. Reddy's Laboratories Ltd. | 8.93% |
Divi's Laboratories Ltd. | 5.56% |
Aurobindo Pharma Ltd. | 5.05% |
Lupin Ltd. | 4.67% |
Alkem Laboratories Ltd. | 3.98% |
Gland Pharma Ltd. | 3.73% |
Mankind Pharma Ltd. | 3.22% |
Zydus Lifesciences Ltd. | 2.96% |
Fund Manager
Name | Kamal Gada | Dharmesh Kakkad |
Start Date | 02 May 2022 | 23 Feb 2021 |
Name
Kamal Gada
Dharmesh Kakkad
Start Date
02 May 2022
23 Feb 2021
About Fund
Description | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 01 Aug 2005 | 25 Jun 2018 |
Description
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
01 Aug 2005
25 Jun 2018
